What is AM-Pharma?
Founded in 2001, AM-Pharma operates at the intersection of advanced clinical development and pharmaceutical manufacturing. The company is primarily focused on the development of recombinant human alkaline phosphatase, a therapeutic candidate designed to mitigate the systemic inflammatory response associated with acute kidney injury. By maintaining a rigorous focus on late-stage clinical trials, AM-Pharma has positioned itself as a pivotal player in the European biotechnology landscape, bridging the gap between academic research and commercial-scale medical solutions. Its operational model emphasizes precision medicine and the development of novel biological therapies that address life-threatening conditions in intensive care settings.
How much funding has AM-Pharma raised?
AM-Pharma has raised a total of $325.2M across 6 funding rounds:
Series A
$781K
Series C
$3M
Series D
$34.5M
Series E
$14.4M
Private Equity
$87.5M
Series F
$185M
Series A (2001): $781K with participation from Biopartners Capital
Series C (2007): $3.1M led by Inventages and Forbion Capital
Series D (2011): $34.5M supported by Forbion, Ysios Capital Partners, Idinvest Partners, Kurma Partners, Inventages, and BB Biotech Ventures
Series E (2014): $14.4M featuring AbbVie, IDInvest Partners, Ysios Capital, Gilde Healthcare, BB Biotech Ventures, and Kuma Biofund
Private Equity (2015): $87.5M backed by Pfizer
Series F (2020): $185M with participation from Ysios Capital, Kurma Partners, Life Sciences Partners, European Investment Bank, BB Pureos Bioventures, Andera Partners, Gilde Healthcare, Cowen Healthcare Investments, and ID Invest Partners
Key Investors in AM-Pharma
Ysios Capital
A leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on developing novel therapies for high unmet medical needs.
Kurma Partners
A prominent European player in the financing of healthcare and biotechnology ventures, specializing in supporting companies from inception through capital expansion to transform scientific discoveries into medical solutions.
Gilde Healthcare
A specialized healthcare investment firm managing over 1.4 billion euros, focusing on businesses that enable better care at lower costs through venture and growth strategies in therapeutics and healthtech.
What's next for AM-Pharma?
Following the recent capital injection, AM-Pharma is well-positioned to accelerate its late-stage clinical programs and expand its manufacturing capabilities. The strategic focus remains on the successful completion of pivotal trials and the subsequent regulatory pathway for its lead therapeutic candidate. By leveraging its deep network of life sciences investors and institutional partners, the company is poised to transition from a development-focused entity to a commercial-stage pharmaceutical leader. Future growth will likely center on scaling production infrastructure and exploring potential market entry strategies for its proprietary therapies, ensuring that its innovative solutions reach patients in critical care environments globally.
See full AM-Pharma company page
